Hormonal
GLP-1 RAs improve histological markers of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and reduce liver fat in patients with MASLD, MetALD, and ALD.
If you have fatty liver disease (MASLD/MASH), GLP-1 medications like Semaglutide or Liraglutide can significantly improve liver inflammation and fat content, often leading to MASH resolution. This is especially beneficial if you also have obesity or Type 2 Diabetes. Discuss these options with your hepatologist, noting that while they improve liver histology, they may not always reverse advanced fibrosis.
A large 72-week double-blind phase II RCT showed that treatment of biopsy-confirmed MASH patients with escalating doses of semaglutide resulted in a significantly higher percentage of MASH resolution, compared to placebo, in a dose-dependent manner.
Why this rating
Supported by large phase II/III RCTs (SUSTAIN-6, LEAN, ESSENCE) and meta-analyses.
Source
Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment?
Lampros Chrysavgis et al. · Biomedicines · 2025
DOI 10.3390/biomedicines13071516
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →